Selected Clinical Trials in Chronic Myeloid Leukemia
1
61 Electronic forwarding or copying is a violation of US and International Copyright Laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1931-6925, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400. Clinical Trials Trial Study Phase Sponsor Contact Information Chemotherapy in Chronic Myeloid Leukemia A Prospective Randomized Phase I/II Study of Clofarabine and Ara-C Versus Clofarabine and Idarubicin Versus Clofarabine plus Idarubicin and Ara-C in Patients with First Relapse or First Salvage of Primary Refractory Acute Myeloid Leukemia (AML); and High-Grade Myelodysplastic Syndrome (MDS) (>/= 10% Blasts); or with Chronic Myeloid Leukemia (CML) in Myeloid Blasts Phase as Front-Line Therapy or in First Salvage Chromosome-Positive Chronic Myeloid Leukemia Vaccines in Chronic Myeloid Leukemia A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease GM-K562 Vaccination for CML Patients with Persistent Disease on Imatinib Mesylate Targeted Agents in Chronic Myeloid Leukemia Efficacy of 400 mg Versus 800 mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet-Transfusion Dependent with or Without Anemia Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib (BMS-354825) Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia with High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination with Peg-Alpha Interferon (PEG-Intron) and Sargramostin (GM-CSF) A Phase IA/II Multicenter, Dose-Escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients with Imatinib-Resistant/ Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/ Refractory Ph+ ALL, and Other Hematologic Malignancies Study of Dasatinib (BMS-354825) in Subjects with Chronic Myelogenous Leukemia with Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome– Positive Leukemias Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients with Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia–Blastic Phase (CML-BP) Phase I Study of PXD101 in Combination with 5-Azacitidine (5-Aza) for Advanced Hematologic Malignancies Phase I Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients with Imatinib Mesylate–Resistant Chronic Phase Chronic Myelogenous Leukemia Stefan H. Faderl, MD 713-745-4613 Jorge E. Cortés, MD 713-794-5783 Hagop M. Kantarjian, MD 713-792-7026 Catherine J. Wu, MD 617-632-5943 Novartis Oncology Clinical Trials Call Center 1-800-340-6843 Schering-Plough Clinical Trial Registry Call Center 1-888-772-8734 Jorge E. Cortés, MD 713-794-5783 Hagop M. Kantarjian, MD 713-792-7026 Jorge E. Cortés, MD 713-794-5783 Novartis Oncology Clinical Trials Line Hotline 1-800-340-6843 Bristol-Myers Squibb Call Center 1-866-892-1BMS Ext. 345 Trial Manager [email protected] Francis J. Giles, MD 713-792-8217 Peggy Green 773-702-0267 Charles Sawyers, MD 310-206-5585 M. D. Anderson Cancer Center/ Genzyme M. D. Anderson Cancer Center/BreakThrough Therapeutics/ Memorial Sloan Kettering/ OHSU Dana-Farber Cancer Institute/ Beth Israel Deaconess Medical Center Novartis Schering-Plough M. D. Anderson Cancer Center/ Bristol-Myers Squibb M. D. Anderson Cancer Center Novartis Bristol-Myers Squibb Wyeth M. D. Anderson Cancer Center/ Novartis University of Chicago/ National Cancer Institute Jonsson Comprehensive Cancer Center/ National Cancer Institute Phase II Phase II Phase I Phase III Phase III Phase II Phase II Phase II Phase II Phase I/II Phase I/II Phase I Phase I Selected Clinical Trials in Chronic Myeloid Leukemia Clinical Leukemia • September 2006
Transcript of Selected Clinical Trials in Chronic Myeloid Leukemia
61
Electronic forwarding or copying is a violation of US and International Copyright Laws.Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP,ISSN #1931-6925, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Clinical Trials
Trial StudyPhase Sponsor Contact Information
Chemotherapy in Chronic Myeloid Leukemia
A Prospective Randomized Phase I/II Study of Clofarabine and Ara-C Versus Clofarabine and Idarubicin Versus Clofarabine plus Idarubicin and Ara-C in Patients with First Relapse or First Salvage of Primary Refractory Acute Myeloid Leukemia (AML); and High-Grade Myelodysplastic Syndrome (MDS) (>/= 10% Blasts); or with Chronic Myeloid Leukemia (CML) in Myeloid Blasts Phase as Front-Line Therapy or in First Salvage Chromosome-Positive Chronic Myeloid Leukemia
Vaccines in Chronic Myeloid Leukemia
A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease
GM-K562 Vaccination for CML Patients with Persistent Disease on Imatinib Mesylate
Targeted Agents in Chronic Myeloid Leukemia
Efficacy of 400 mg Versus 800 mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients
A Pivotal Randomized Study of Lonafarnib Versus Placebo in the Treatment of Subjects with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet-Transfusion Dependent with or Without Anemia
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib (BMS-354825)
Randomized Trial of Therapy of Early Phase Chronic Myelogenous Leukemia with High-Dose Imatinib Mesylate (Gleevec) Alone or in Combination with Peg-Alpha Interferon (PEG-Intron) and Sargramostin (GM-CSF)
A Phase IA/II Multicenter, Dose-Escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients with Imatinib-Resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies
Study of Dasatinib (BMS-354825) in Subjects with Chronic Myelogenous Leukemia with Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate
A Phase 1/2 Study of SKI-606 in Philadelphia Chromosome– Positive Leukemias
Ph I/II Study of PTK 787 (Vatalanib) and Gleevec (Imatinib) in Patients with Refractory Acute Myelogenous Leukemia (AML), Agnogenic Myeloid Metaplasia (AMM), and Chronic Myelogenous Leukemia–Blastic Phase (CML-BP)
Phase I Study of PXD101 in Combination with 5-Azacitidine (5-Aza) for Advanced Hematologic Malignancies
Phase I Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients with Imatinib Mesylate–Resistant Chronic Phase Chronic Myelogenous Leukemia
Stefan H. Faderl, MD713-745-4613
Jorge E. Cortés, MD713-794-5783
Hagop M. Kantarjian, MD713-792-7026
Catherine J. Wu, MD617-632-5943
Novartis Oncology ClinicalTrials Call Center1-800-340-6843
Schering-Plough ClinicalTrial Registry Call Center
1-888-772-8734
Jorge E. Cortés, MD713-794-5783
Hagop M. Kantarjian, MD713-792-7026
Jorge E. Cortés, MD713-794-5783
Novartis Oncology ClinicalTrials Line Hotline1-800-340-6843
Bristol-Myers Squibb Call Center1-866-892-1BMS Ext. 345
Trial [email protected]
Francis J. Giles, MD713-792-8217
Peggy Green773-702-0267
Charles Sawyers, MD310-206-5585
M. D. AndersonCancer Center/
Genzyme
M. D. Anderson CancerCenter/BreakThrough
Therapeutics/Memorial Sloan Kettering/
OHSU
Dana-FarberCancer Institute/
Beth Israel DeaconessMedical Center
Novartis
Schering-Plough
M. D. AndersonCancer Center/
Bristol-Myers Squibb
M. D. AndersonCancer Center
Novartis
Bristol-Myers Squibb
Wyeth
M. D. AndersonCancer Center/
Novartis
University of Chicago/National Cancer
Institute
Jonsson ComprehensiveCancer Center/National Cancer
Institute
Phase II
Phase II
Phase I
Phase III
Phase III
Phase II
Phase II
Phase II
Phase II
Phase I/II
Phase I/II
Phase I
Phase I
Selected Clinical Trials in Chronic Myeloid Leukemia
Clinical Leukemia • September 2006
CLK 1.1 CT list.indd 1 9/7/06 10:44:50 AM
